Download video

Clinical Pharmacy Course Online: Join Our Online Clinical Pharmacy Training Today

13 views

Clinical Pharmacy Courses

9 days ago

Clinical Pharmacy Course Online: Join Our Online Clinical Pharmacy Training Today

Clinical Pharmacy Course Online: Join Our Online Clinical Pharmacy Training Today

New Drug Approvals Inluriyo (imlunestrant), Palsonify (paltusotine), and Rhapsido (remibrutinib)
18:30
New Drug Approvals Inluriyo (imlunestrant), Palsonify (paltusotine), and Rhapsido (remibrutinib)
by Medication Academy
Top 10 Clinical Pharmacy Skills You Should Master | PART 2 | Clinical Pharmacy Course
33:45
Top 10 Clinical Pharmacy Skills You Should Master | PART 2 | Clinical Pharmacy Course
by Clinical Pharmacy Courses
Real-world efficacy of second-line cabozantinib in renal cell carcinoma
0:40
Real-world efficacy of second-line cabozantinib in renal cell carcinoma
by VJOncology
Q1 Q2 Q3 De-formulation \& Equivalence
5:55
Q1 Q2 Q3 De-formulation \& Equivalence
by Pharma Learning In Depth
ClinPGx Meeting 2024 Day 1 11 50 12 20 State of the Art with Clinical Labs
26:35
ClinPGx Meeting 2024 Day 1 11 50 12 20 State of the Art with Clinical Labs
by PharmGKB
CPIC guideline for serotonin reuptake inhibitors and CYP2D6, HTR2A and SLC6A4 - no recommendations
3:34
CPIC guideline for serotonin reuptake inhibitors and CYP2D6, HTR2A and SLC6A4 - no recommendations
by PharmGKB
CPIC guideline for sertraline and CYP2C19, CYP2B6
10:43
CPIC guideline for sertraline and CYP2C19, CYP2B6
by PharmGKB
Analytical Session PharmaSynergyOTC 2025 1
1:08:22
Analytical Session PharmaSynergyOTC 2025 1
by Lynx2Market
HIV Medication Classes #saroarakelians #pharmacytalkusa #hivprevention
3:24
HIV Medication Classes #saroarakelians #pharmacytalkusa #hivprevention
by Pharmacy Talk USA
Q2 2025 FDA New Drug Approvals
48:37
Q2 2025 FDA New Drug Approvals
by Medication Academy
CPIC guideline for citalopram, escitalopram and CYP2C19
9:49
CPIC guideline for citalopram, escitalopram and CYP2C19
by PharmGKB
Pharmacology - 11: NCLEX 2025-Critical Thinking, Patient Safety \& Expert Nursing Practice Scenario
14:43
Pharmacology - 11: NCLEX 2025-Critical Thinking, Patient Safety \& Expert Nursing Practice Scenario
by Nursing McQs
The potential of MDM2 inhibitors in MPNs: past and ongoing studies of navtemadlin
9:54
The potential of MDM2 inhibitors in MPNs: past and ongoing studies of navtemadlin
by VJHemOnc – Video Journal of Hematology \& HemOnc
Clinical Pharmacy Explained: Roles, Skills, and Career Opportunities in 2025
26:09
Clinical Pharmacy Explained: Roles, Skills, and Career Opportunities in 2025
by Clinical Pharmacy Courses
Optimizing the combination of ibrutinib plus venetoclax in CLL
2:46
Optimizing the combination of ibrutinib plus venetoclax in CLL
by VJHemOnc – Video Journal of Hematology \& HemOnc
Targeting Cancer at the Molecular Level: Repurposed Drugs and Integrative Strategies
58:39
Targeting Cancer at the Molecular Level: Repurposed Drugs and Integrative Strategies
by Fit Rx Health + Wellness
Pharmacology for NCLEX 2025: A Comprehensive Guide to Drug Therapy, Side Effects, and Dosing
34:00
Pharmacology for NCLEX 2025: A Comprehensive Guide to Drug Therapy, Side Effects, and Dosing
by Nursing McQs
CPIC guideline for venlafaxine and CYP2D6
6:30
CPIC guideline for venlafaxine and CYP2D6
by PharmGKB
S2. Ep 9: A patient perspective - navigating chronic disease and pharma's role in improving lives
18:41
S2. Ep 9: A patient perspective - navigating chronic disease and pharma's role in improving lives
by Reuters Events Pharma
22SW19 - Alternatives to Polypharmacy in Conditions of Neurologic Impairment
3:24
22SW19 - Alternatives to Polypharmacy in Conditions of Neurologic Impairment
by Herbal Educational Services
Inside Clinical Trials: From Lab Bench to Pharmacy Shelf
12:40
Inside Clinical Trials: From Lab Bench to Pharmacy Shelf
by GCP-Mindset - All About Clinical Research
Medicus Pharma advances Phase 2 clinical study, eyes FDA fast-track approval
5:08
Medicus Pharma advances Phase 2 clinical study, eyes FDA fast-track approval
by Proactive Investors